PathoGenesis Report issue

For profit Phase 3
Founded: Seattle WA United States (1992)
Status: Acquired by Chiron (2000) → now Novartis (2006)

Organization Overview

First Clinical Trial
1995
NCT00004829
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
1995

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Pathogenesis

Active Ingredients

Drugs in Phase 3 Trials (1)

tobramycin (nebcin) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Bacterial Infections (Phase 3)

Cystic Fibrosis (Phase 3)

Fibrosis (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 1